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MaOBJECTIVES The aim of this study was to examine whether manual thrombus aspiration reduces microvascular
obstruction assessed by cardiac magnetic resonance imaging in patients with ST-segment elevation myocardial infarction
(STEMI) presenting late after symptom onset.
BACKGROUND Thrombus aspiration is an established treatment option in patients with STEMI undergoing primary
percutaneous coronary intervention (PCI). However, there are only limited data on the efﬁcacy of thrombus aspiration in
patients with STEMI presenting $12 h after symptom onset.
METHODS Patients with subacute STEMI presenting $12 and #48 h after symptom onset were randomized to primary
PCI with or without manual thrombus aspiration in a 1:1 ratio. Patients underwent cardiac magnetic resonance imaging
1 to 4 days after randomization. The primary endpoint was the extent of microvascular obstruction.
RESULTS A total of 152 patients underwent randomization. The mean time between symptom onset and PCI was
28  12 h. Baseline characteristics were comparable between groups. The majority of patients (60%) showed at least a
moderate amount of viable myocardium in the affected region. Extent of microvascular obstruction was not signiﬁcantly
different between patients assigned to thrombus aspiration and the control group (2.5  4.0% vs. 3.1  4.4% of left
ventricular mass, p ¼ 0.47). There were also no signiﬁcant differences in infarct size, myocardial salvage, left ventricular
ejection fraction, and angiographic and clinical endpoints between groups.
CONCLUSIONS In this ﬁrst randomized trial of thrombectomy in patients with STEMI presenting late after symptom
onset, routine thrombus aspiration before PCI failed to show a beneﬁt for markers of reperfusion success. (Effect of
Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset; NCT01379248)
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ABBR EV I A T I ON S
AND ACRONYMS
CMR = cardiac magnetic
resonance imaging
LV = left ventricular
%LV = percentage of
left ventricular mass
MSI = myocardial salvage index
MVO = microvascular
obstruction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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114T hrombus aspiration is an establishedtreatment option in patients withST-segment elevation myocardial
infarction (STEMI) undergoing primary per-
cutaneous coronary intervention (PCI), al-
though recent trials reported disappointing
results, with no reduction in mortality and
possibly an increase in stroke (1,2). Current
evidence is restricted largely to patients pre-
senting within the ﬁrst hours after symptom
onset. Nevertheless, patients presenting
$12 h after the beginning of symptoms may
display particularly high thrombus burden
because of long dwelling times. Thus,
thrombus aspiration might be a useful
adjunct to conventional PCI in this subset ofpatients. A prior study suggested that thrombus aspi-
ration may indeed be more effective in late-
presenting patients (3). However, thrombectomySEE PAGE 123could also be detrimental in this situation because
of mechanical thrombus dislodgment and distal
embolization with subsequent microvascular injury
and expansion of the necrotic zone. Thrombus
composition may also play a role. Although in the
initial stages of evolving infarction, thrombotic mate-
rial is relatively soft (low ﬁbrin content, high platelet
content), it becomes more organized (high ﬁbrin con-
tent, low platelet content) and possibly less suited for
aspiration at later stages (4). However, data on the ef-
ﬁcacy of thrombus aspiration in the subgroup of pa-
tients with STEMI presenting late after symptom
onset are scarce.
In the present trial, we examined the effect of
routine thrombus aspiration on microvascular
obstruction (MVO) assessed by cardiac magnetic reso-
nance imaging (CMR) in patients with subacute STEMI
presenting between 12 and 48 h after symptom onset.
METHODS
DESIGN OVERVIEW. The trial’s main objective was to
study whether manual thrombus aspiration reduces
MVO in patients with subacute STEMI. Eligible pa-
tients were randomized to primary PCI with or
without manual thrombus aspiration. The main in-
clusion criteria were STEMI $12 and #48 h after
symptom onset, irrespective of signs of ongoing
ischemia, and age between 18 and 90 years. Exclusion
criteria included prior thrombolysis, contraindica-
tions to CMR (known at the time of randomization),
and severe comorbidities with limited life expectancy
(<6 months). Patients underwent CMR 1 to 4 daysafter randomization. The primary efﬁcacy endpoint
was the extent of MVO on late gadolinium enhance-
ment CMR. All patients were enrolled at a single
institution (University of Leipzig-Heart Center).
The study was approved by the local institutional
review board and conducted in accordance with
the principles of the Declaration of Helsinki. All pa-
tients provided written informed consent before
randomization.
RANDOMIZATION AND BLINDING. Eligible patients
willing to take part in the study were assigned in a
1:1 ratio to the treatment groups by permuted block
randomization with randomly changing block sizes
using an Internet-based system and a computer-
generated list of random numbers. Randomization
was performed before coronary angiography in the
catheterization laboratory. The randomization list
was generated and maintained by an information
technology expert who was not involved in the clin-
ical conduct of the study.
CMR and all other subsequent analyses were per-
formed by readers blinded to treatment assignment.
By design, physicians performing the invasive pro-
cedures were aware of randomization results. Pa-
tients were not informed about treatment allocation
until completion of the study.
ENDPOINTS. The primary efﬁcacy endpoint was the
extent of MVO assessed by CMR in the modiﬁed
intention-to-treat population. Secondary CMR end-
points included infarct size, myocardial salvage, and
left ventricular (LV) volumes and ejection fraction.
Furthermore, a central blinded analysis of angio-
graphic markers of reperfusion success, such as the
Thrombolysis In Myocardial Infarction (TIMI) ﬂow
post-PCI and myocardial blush grade, was performed.
Coronary collateralization was graded according to
the Rentrop classiﬁcation (grade 0, no visible ﬁlling of
any collateral channel; grade 1, ﬁlling of the side
branches of the infarct-related artery; grade 2, partial
ﬁlling of the epicardial vessel of the infarct-related
artery; grade 3, complete collateral ﬁlling of the
epicardial vessel) (5). For enzymatic infarct size
determination, high-sensitivity troponin T after
24 and 48 h was evaluated. The clinical endpoints
of all-cause and cardiovascular death, myocardial
reinfarction, target vessel revascularization, stent
thrombosis, and stroke were reported up to 30 days
after randomization. Clinical endpoints were deﬁned
according to guidelines (6).
PCI. Thrombus aspiration had to be performed before
the ﬁrst balloon inﬂation using a 6-F manual aspira-
tion catheter (Export AP; Medtronic, Minneapolis,
FIGURE 1 Cardiac Magnetic Resonance Imaging Analysis
Patient with subacute ST-segment elevation myocardial infarction (STEMI) presenting 21 h after symptom onset. (A) Proximal occlusion of left
anterior descending coronary artery (arrow). (B) Contrast-enhanced cardiac magnetic resonance imaging (CMR) showing transmural ante-
roseptal necrosis with a marked core of microvascular obstruction (MVO). (C) Computer-aided signal intensity analysis of MVO and infarct size.
The yellow overlay (infarct size) indicates a signal intensity of >5 SDs compared with remote, healthy myocardium. The yellow and brown
overlay within the infarct indicates the computer detected zone of MVO.
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115Minnesota). A minimum of 2 aspiration passages
across the lesion was recommended. Otherwise, PCI
was performed according to current best practice.
CMR. Patients underwent CMR 1 to 4 days after
randomization for the evaluation of the primary
endpoint MVO and selected secondary endpoints
(infarct size, myocardial salvage, and LV ejection
fraction and volumes). The scan protocol on a clini-
cal 1.5-T scanner has been used in several other ran-
domized trials and has been described in detail
previously (7). In brief, infarct size and MVO were
assessed in late gadolinium enhancement short-axis
images covering the left ventricle approximately
15 min after the injection of gadolinium chelate. An
inversion-recovery turbo gradient-echo sequence was
used for image acquisition. A hypointense core within
the hyperenhanced infarcted area was deﬁned as
MVO. For determination of infarct-related myocardial
edema/area at risk, short-axis slices covering the left
ventricle using a T2-weighted triple-inversion recov-
ery turbo spin echo sequence before contrast admin-
istration were obtained. Assessment of LV function
and volumes was performed in short-axis slices from
base to apex acquired using a standard steady-state
free precession technique.
CMR images were sent on storable media to the
CMR core laboratory at the University Heart Center
Lübeck for assessment by fully blinded operators. For
all quantitative analyses, certiﬁed CMR evaluation
software was used (cmr42, Circle Cardiovascular
Imaging, Calgary, Alberta, Canada). Semiautomated
computer-aided threshold detection was used to
identify regions of edema, MVO, and infarcted
myocardium. A myocardial region was regarded as
affected if at least 10 adjacent myocardial pixelsrevealed a signal intensity of >2 SDs of remote
healthy myocardium for edema and >5 SDs in late
gadolinium enhancement images (Figure 1). MVO and
infarct size were expressed as percentage of LV mass
(%LV), given by the sum of the mass of MVO and late
gadolinium enhancement regions for all slices
divided by the overall mass of the LV myocardial
cross-sectional slices. If present, MVO was included
in the overall infarct size and was quantiﬁed sepa-
rately. Myocardial salvage index (MSI) was calculated
as area at risk minus infarct size divided by area at
risk multiplied by 100, as previously described (8).
The core laboratory has vast experience in CMR
image acquisition and post-processing (9,10).
SAMPLE SIZE. Sample size was calculated for the
between-group comparison with regard to the pri-
mary endpoint. From the results of a previous study
and internal data, we expected a mean difference
of 2.0% LV in the extent of MVO between the treat-
ment arms, with an SD of 3.5 (11). On the basis of these
assumptions, a total of 132 patients needed to be
analyzed to reject the null hypothesis of equal means
between the 2 groups with statistical power of 90%
(2-tailed Student t test, a ¼ 0.05). To account for a
presumed rate of 15% of patients not undergoing CMR
or without analyzable examinations, a total of 152
patients were randomized. Sample size was calcu-
lated using SiZ (Cytel, Cambridge, Massachusetts).
STATISTICAL ANALYSIS. Categorical variables are
expressed as number and percentage of patients.
Continuous data are reported as mean  SD as well
as 95% conﬁdence intervals when appropriate. Cor-
relations were investigated using Spearman’s corre-
lation coefﬁcient. Patient characteristics were
compared using the Fisher exact test for categorical
FIGURE 2 Study Flow
Study ﬂowchart showing the number of randomized patients and patients with primary endpoint assessment. CMR ¼ cardiac magnetic reso-
nance imaging; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction. *Of the 69 patients who
received the allocated treatment, 18 did not undergo CMR.
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116variables and independent-samples Student t tests
as well as analysis of variance for continuous
data. Data were analyzed for both a modiﬁed
intention-to-treat (cohort for primary endpoint anal-
ysis) and a per protocol population. The modiﬁed
intention-to-treat cohort comprised all patients with
subacute STEMI who underwent randomization irre-
spective of treatment actually received or protocol
adherence. On the basis of angiographic, laboratory,
and CMR imaging results (normal coronary arteries,
no elevation of cardiac enzymes, no edema), patients
with ﬁnal diagnoses other than STEMI were excluded
(n ¼ 8). The per-protocol analysis included all pa-
tients with subacute STEMI who received treatment
according to the initial allocation.
Two-tailed p values <0.05 were considered to indi-
cate statistical signiﬁcance. Statistical analyses were
performed with SPSS version 17.0 (SPSS, Chicago,
Illinois).RESULTS
BASELINE CHARACTERISTICS. From March 2011
through November 2014, a total of 152 patients un-
derwent randomization (Figure 2). Eight patients
were excluded from the analysis because of ﬁnal
diagnoses other than STEMI.
Baseline characteristics were well balanced
between the 2 treatment groups (Table 1). The mean
time between symptom onset and PCI was 28  12 h
for the overall cohort (p ¼ 0.17 for between-group
comparison). The aspiration catheter could not be
advanced to the culprit site in 5 patients. Three pa-
tients randomized to PCI alone underwent thrombus
aspiration by operator’s choice (bailout situations due
to unsatisfactory results after conventional PCI).
Thrombectomy led to aspiration of macroscopic
thrombus material in >60% of patients (Table 1).
Administration of glycoprotein IIb/IIIa receptor
TABLE 1 Baseline and Procedural Characteristics
Thrombus
Aspiration
Standard
PCI Only
(n ¼ 70) (n ¼ 74)
Age, yrs 66  12 66  15
Men 48/70 (69) 59/74 (80)
Hypertension 55/70 (79) 48/74 (65)
Current smoking 25/70 (36) 31/72 (43)
Hyperlipoproteinemia 11/70 (16) 17/74 (23)
Diabetes mellitus 22/70 (31) 25/74 (34)
Cardiogenic shock 2/70 (3) 4/74 (5)
Prior myocardial infarction 2/70 (3) 4/74 (5)
Prior coronary artery bypass surgery 2/70 (3) 0
Body mass index, kg/m2 28.9  3.8 28.6  4.7
Glomerular ﬁltration rate,
ml/min/1.73 m2*
86  27 79  26
Ongoing signs of ischemia on admission 28/57 (49) 34/62 (55)
Door-to-balloon-time, min 78  150 62  105
Symptom-onset-to-balloon-time, h 26  13 29  12
Infarct-related coronary artery
Left anterior descending 38/70 (54) 32/72 (44)
Left circumﬂex 11/70 (16) 9/72 (13)
Right 21/70 (30) 31/72 (43)
TIMI ﬂow before PCI
0 44/70 (63) 46/74 (62)
1 3/70 (4) 2/74 (3)
2 14/70 (20) 13/74 (18)
3 9/70 (13) 12/74 (18)
TIMI thrombus grade before wire crossing
0 (no thrombus) 5/70 (7) 12/74 (16)
1 (possible thrombus) 1/70 (1) 1/74 (1)
2 (deﬁnite thrombus, <0.5  vessel
diameter)
2/70 (3) 0/74
3 (deﬁnite thrombus, 0.5–2  vessel
diameter)
8/70 (11) 4/74 (5)
4 (deﬁnite thrombus, >2  vessel
diameter)
9/70 (13) 11/74 (15)
5 (total occlusion) 44/70 (63) 46/74 (62)
Killip class at presentation
I 61/70 (87) 61/74 (82)
II 5/70 (7) 8/74 (11)
III 2/70 (3) 1/74 (1)
IV 2/70 (3) 4/74 (5)
Cardiogenic shock 2/70 (3) 4/74 (5)
Myocardial blush grade before PCI
0 52/70 (74) 53/74 (72)
1 5/70 (7) 4/74 (5)
2 4/70 (6) 6/74 (8)
3 9/70 (13) 11/74 (15)
Multivessel disease 38/70 (54) 44/74 (60)
Pre-dilation† 27/70 (39) 54/72 (75)
Post-dilation 7/69 (10) 14/72 (19)
Visible thrombus in aspirate‡ 31/51 (61) 2/3 (67)
Continued in the next column
TABLE 1 Continued
Thrombus
Aspiration
Standard
PCI Only
(n ¼ 70) (n ¼ 74)
Drug-eluting stent 50/69 (73) 44/72 (61)
Number of stents 1.6  0.9 1.8  1.2
Long-term medication before
hospital admission
Aspirin 61/70 (87) 55/74 (74)
Thienopyridine 36/70 (51) 33/74 (45)
Statin 11/70 (16) 15/74 (20)
Beta-blocker§ 38/70 (54) 27/74 (37)
ACE inhibitor/angiotensin
receptor antagonist
36/70 (51) 37/74 (50)
Oral anticoagulant agent 2/70 (3) 4/74 (5)
Values are mean  SD and n/N (%). *Estimated according to the MDRD (Modiﬁ-
cation of Diet in Renal Disease) formula. †p < 0.001. ‡3 patients randomized to
PCI alone underwent bailout thrombus aspiration (crossover). §p ¼ 0.04.
ACE ¼ angiotensin-converting enzyme; PCI ¼ percutaneous coronary interven-
tion; TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 2 Results of Cardiac Magnetic Resonance Imaging
Thrombus
Aspiration
Standard
PCI Only
p Value(n ¼ 56) (n ¼ 55)
Time from PCI to CMR, days 2.2  1.5 2.4  2.4 0.66
LV mass, g 147  45 140  36 0.36
Microvascular obstruction, g 4.2  7.8 4.7  7.5 0.77
Microvascular obstruction, %LV 2.5  4.0 3.1  4.4 0.47
Infarct size, g 44.0  28.0 38.6  26.8 0.32
Infarct size, %LV 29.5  16.6 27.2  16.7 0.49
Area at risk, g 57.0  28.6 49.6  23.9 0.17
Area at risk, %LV 38.9  16.1 37.1  16.3 0.59
Myocardial salvage, g 12.5  8.5 11.8  12.7 0.77
Myocardial salvage index,
% area at risk
26.2  21.2 28.8  30.8 0.63
LV ejection fraction, % 46.4  10.7 44.8  11.5 0.44
LV end-diastolic volume, ml 160  52 157  42 0.77
LV end-systolic volume, ml 88  38 89  34 0.89
Values are mean  SD.
CMR ¼ cardiac magnetic resonance imaging; LV ¼ left ventricular; PCI ¼ percutaneous coronary
intervention; %LV ¼ percentage of left ventricular mass.
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117inhibitors was similar between groups (18 patients
[25%] in the thrombus aspiration group vs. 21 [28%] in
the control group, p ¼ 0.85).
IMPACT OF THROMBECTOMY ON CMR PARAMETERS.
MVO was present in 59% (n ¼ 33) and 64% (n ¼ 35) ofpatients after thrombectomy and conventional PCI,
respectively (p ¼ 0.69). The primary endpoint, extent
of MVO, was 2.5  4.0%LV in patients assigned to
thrombus aspiration and 3.1  4.4%LV in patients
randomized to the control group (p ¼ 0.47) (Table 2,
Figure 3). There were also no signiﬁcant differences in
infarct size, MSI, and LV volumes or ejection fraction
between groups (Table 2). The results were consistent
across all subgroups (Figure 4) and did not change
substantially when analyzing only the per protocol
population.
ANGIOGRAPHIC AND PROCEDURAL OUTCOME.
The majority of patients (n ¼ 90 [62.5%]) displayed
FIGURE 3 Extent of Microvascular Obstruction With and
Without Thrombus Aspiration
Shown is the mean extent of microvascular obstruction (MVO)
between patients assigned to percutaneous coronary interven-
tion (PCI) with and without thrombus aspiration. Error bars
display 95% conﬁdence intervals. %LV ¼ percentage of left
ventricular mass.
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118complete occlusion of the culprit vessel before PCI
corresponding to thrombus grade 5 (Table 1). Coro-
nary collateral vessels were present in 89 patients
(62%), with no differences between the groups
(p ¼ 0.23). In the thrombectomy group, signiﬁcantly
more patients underwent primary stenting without
pre-dilation of the lesion (p < 0.001; Table 1).
Post-interventional TIMI ﬂow grade 3 was achieved
in 54 patients (78%) in the thrombectomy group and
50 patients (69%) in the control group with conven-
tional PCI only (p ¼ 0.44). Myocardial blush grade
after PCI was not signiﬁcantly different between
groups (grade 3, 70.0% vs. 64.9%; p ¼ 0.83).
ENZYMATIC INFARCT SIZE. Enzymatic infarct size
assessed by high-sensitivity troponin T values was
similar between the thrombectomy and the standard
PCI groups, with 3,031  2,189 ng/l versus 2,588 
1,908 ng/l at 24 h (p ¼ 0.24) and 2,995  2,395 ng/l
versus 3,150  2,140 ng/l (p ¼ 0.75) at 48 h.
CLINICAL OUTCOMES. Follow-up at 30 days was
completed in all patients. The clinical event rate was
low (Table 3). Overall, 16 events were recorded. One
patient who did not undergo thrombus aspiration had
a stroke several hours after catheterization.
With respect to early clinical outcomes, no sig-
niﬁcant differences between the groups could be
observed (Table 3). The mortality rate at 30 days was
2.9% (n ¼ 2) in patients undergoing thrombectomyversus 5.4% (n ¼ 4) in those undergoing standard PCI
only (p ¼ 0.68).
REPERFUSION SUCCESS. CMR was performed a
mean of 2.3  2.0 days after PCI, with no signiﬁcant
difference between groups (p ¼ 0.66). A total of 33
patients did not undergo CMR or had nonanalyzable
images (Figure 2).
LV ejection fraction was moderately impaired
(45  11%). At an area at risk of 38  16%LV and a ﬁnal
infarct size of 28  17%LV, MSI was 27  26. The
majority of patients (60%) had MSIs >10. MSI did not
differ between asymptomatic patients and those with
ongoing ischemic symptoms (33  29 vs. 26  25;
p ¼ 0.31). MSI was higher in patients with preserved
or residual epicardial ﬂow of TIMI ﬂow grades 3 and
2 before reperfusion compared with those with
severely compromised or absent ﬂow of TIMI ﬂow
grades 1 and 0 (43  32 vs. 21  20; p < 0.001). Patients
with at least a minimum of angiographically visible
collateral vessels (Rentrop grades 1 to 3) displayed
higher MSI in comparison with those without (37  30
vs. 21  21; p ¼ 0.004). MSI, infarct size, and MVO
showed no signiﬁcant difference between patients in
the shortest, intermediate, and longest tertiles of
symptom onset–to–PCI times (Figure 5). There were
no correlations of MSI (p ¼ 0.30), infarct size
(p ¼ 0.80), and MVO (p ¼ 0.41) with symptom onset–
to–balloon time.
DISCUSSION
This was the ﬁrst randomized controlled study to
examine a possible beneﬁcial effect of routine manual
thrombus aspiration exclusively in patients with
subacute STEMI. Furthermore, we report on the
largest cohort of late-presenting STEMI patients un-
dergoing CMR imaging for the assessment of reper-
fusion success. The main ﬁndings can be summarized
as follows: 1) aspiration thrombectomy did not reduce
the extent of MVO compared with standard PCI
without thrombectomy, which was corroborated by a
lack of beneﬁt in secondary endpoints; and 2) pa-
tients with STEMI with symptom onset–to–reperfu-
sion times >12 h had only a moderate amount of
salvageable myocardium.
THROMBUS ASPIRATION IN STEMI. Previous ran-
domized trials evaluating the effects of thrombus
aspiration in STEMI have focused mainly on patients
within 12 h of symptom onset. A medium-sized study
showed a reduction in the extent of MVO and reduced
infarct size after thrombectomy (11). In line with these
results, the single-center TAPAS (Thrombus Aspira-
tion During Percutaneous Coronary Intervention in
FIGURE 4 Subgroup Analysis for the Primary Endpoint, Extent of Microvascular Obstruction
Mean difference and 95% conﬁdence intervals in the primary endpoint of microvascular obstruction (MVO) between the standard PCI
(percutaneous coronary intervention) group and the thrombectomy group for pre-deﬁned subgroups. GP ¼ glycoprotein; TIMI ¼ Thrombolysis
In Myocardial Infarction.
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119Acute Myocardial Infarction Study) found improve-
ments in angiographic as well as electrocardiographic
markers of reperfusion success and even reductions
in all-cause and cardiac death at 1 year (12,13). These
positive initial results were recently challenged byTABLE 3 Clinical Events at 30 Days
Thrombus
Aspiration
Standard
PCI Only
p Value(n ¼ 70) (n ¼ 74)
All-cause death 2 (3) 4 (5) 0.68
Cardiovascular death 2 (3) 3 (4) 1.00
Reinfarction 0 0 —
Target vessel revascularization 2 (3) 0 0.24
Target lesion revascularization 2 (3) 0 0.24
Stent thrombosis 0 0 —
Stroke 0 1 (1) 0.24
Values are n (%).
PCI ¼ percutaneous coronary intervention.several large trials: the INFUSE-AMI (Intracoronary
Abciximab and Aspiration Thrombectomy in Patients
With Large Anterior Myocardial Infarction) study did
not reveal a beneﬁcial effect of thrombus aspiration
on infarct size assessed by CMR in patients with
anterior STEMI presenting very early after symptom
onset (14). The multicenter TASTE (Thrombus Aspi-
ration in ST-Elevation Myocardial Infarction in Scan-
dinavia) study randomized 7,244 patients to manual
thrombus aspiration followed by PCI versus PCI only
(1). There was a beneﬁcial effect of thrombectomy
neither on the primary endpoint of all-cause mortal-
ity nor on any other clinical endpoint. The largest trial
to date (TOTAL [Trial of Routine Aspiration Throm-
bectomy With PCI Versus PCI Alone]) in 10,732 pa-
tients with acute STEMI conﬁrmed these neutral
results on mortality but found an increased stroke
rate at 30 days after thrombus aspiration (2). Consis-
tent with these results, in a recent meta-analysis, the
investigators concluded that in STEMI, aspiration
thrombectomy before primary PCI is not associated
FIGURE 5 Cardiac Magnetic Resonance Imaging Parameters According to Time From Symptom Onset to Reperfusion
Shown is the mean extent of myocardial salvage index (MSI) (A), infarct size (B), and microvascular obstruction (MVO) (C) according to the time from symptom onset to
reperfusion (12 to 24, >24 to 36, and >36 to 48 h). Error bars display 95% conﬁdence intervals. %LV ¼ percentage of left ventricular mass.
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crease the risk for stroke (15). The same likely holds
true for patients with non–ST-segment elevation
myocardial infarction (10). The results from TASTE
and TOTAL have not yet found their way into treat-
ment guidelines, which still express a moderate
recommendation for routine manual thrombectomy
in all patients with STEMI (16,17).
It is important to realize that there are only scarce
data on the efﬁcacy of thrombus aspiration in patients
who present later than 12 h after symptom onset.
Although the aforementioned TASTE trial had a lib-
eral inclusion window of 24 h after initial symptoms,
the vast majority of patients presented within the
ﬁrst hours (the median time between symptom onset
and PCI was 3 h).
Several hypotheses might serve to explain why
thrombus aspiration failed in the majority of recent
trials, including ours, despite being a theoretically
sound concept. First, aspiration will remove throm-
botic material in many patients (as veriﬁed by anal-
ysis of the aspirate), but manipulation with the
catheter might also dislodge thrombotic material,
with subsequent embolization into the microcircula-
tion. These opposing effects might balance each
other, resulting in a neutral outcome.
Second, the magnitude of the presumed net effect
of thrombus aspiration might not be enough to pro-
duce changes in the extent of MVO or other surrogate
parameters of reperfusion success. This might be
especially true in a late-presenting cohort in which,
because of high thrombus burden, the potential for
signiﬁcant iatrogenic distal embolization is likelyhigher than in patients presenting early after symp-
tom onset. However, thrombus aspiration in the ﬁrst
hours of infarction revealed equally sobering results.
In the INFUSE-AMI trial, which randomized only pa-
tients with large anterior infarctions within 4 h of
symptom onset, manual thrombus aspiration did not
affect infarct size measured by CMR (14). Subgroup
analyses from the TASTE and TOTAL trials also found
no reductions in clinical events in patients with the
shortest symptom onset–to–PCI times (1,2). Speciﬁc to
subacute stages of STEMI, the amount of myocardium
to be salvaged may also be too small for thrombus
aspiration to effectively affect infarct size. In the
present trial, we explored the unselected routine use
of thrombus aspiration before PCI in patients with
subacute STEMI. However, it is possible that
thrombus aspiration might be advantageous only in
speciﬁc subsets of patients, such as those with large
thrombus burden, total occlusion, or reduced ﬂow.
However, almost 90% of patients in our trial dis-
played either complete vessel occlusion or high
thrombus burden (thrombus grades 3–5), making this
an unlikely explanation for the neutral results.
REPERFUSION SUCCESS AND PRIMARY PCI IN
SUBACUTE STEMI. There is general consensus that
primary PCI is the treatment of choice for patients
with STEMI who present within 12 h of symptom
onset. Data are much less clear for patients presenting
thereafter. Recent treatment guidelines recommend
considering reperfusion therapy with primary PCI in
patients with STEMI with symptom duration of 12 to
48 h (18).
PERSPECTIVES
WHAT IS KNOWN? Patients with STEMI presenting within 12 h
after symptom onset do not beneﬁt from routine manual
thrombus aspiration in the infarct-related artery. It is unclear
whether thrombectomy may be a treatment option in late-
presenting patients between 12 and 48 h, who often display
particularly high thrombus burden.
WHAT IS NEW? Patients with STEMI presenting late after
symptom onset do not beneﬁt from routine manual aspiration
thrombectomy before PCI.
WHAT IS NEXT? Treatment modalities other than routine
thrombus aspiration are needed to further reduce microvascular
injury in patients with STEMI.
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121The theoretical consideration favoring reperfusion
over medical therapy in subacute STEMI is the
hypothesis that a signiﬁcant amount of viable
myocardium that can still be salvaged despite pro-
longed ischemia is present. Factors such as a stut-
tering course with intermittent occlusion and
recanalization, ischemic preconditioning, persis-
tence of minimal ﬂow in the infarct-related artery,
or recruitment of collateral vessels may prevent
complete necrosis and preserve some degree of
myocardial viability (19–23). The present study is the
ﬁrst to study the hypothesis by means of CMR
demonstrating a moderate amount of viable
myocardium in patients presenting between 12 and
48 h after symptom onset. However, these ﬁndings
cannot be interpreted as being supportive of a
beneﬁcial effect of mechanical reperfusion, as all
patients underwent PCI. Only a few prospective
studies have investigated the value of late me-
chanical reperfusion. In the BRAVE 2 (Beyond 12
Hours Reperfusion Alternative Evaluation 2) trial,
335 asymptomatic patients with STEMI presenting 12
to 48 h after symptom onset were randomized to
immediate invasive or conservative treatment (23).
Infarct size by single-photon emission computed
tomography was signiﬁcantly smaller with the
invasive strategy, which might translate into a
reduction in mortality observed at long-term
follow-up (24). The OAT (Occluded Artery Trial)
randomized 2,166 late-presenting clinically stable
post-STEMI patients with occluded infarct-related
arteries to either PCI or medical treatment. PCI was
not associated with a reduction in clinical events
compared with conservative therapy (25). However,
OAT is hardly comparable with the present trial
because it differs in several key aspects. First, OAT
enrolled patients presenting between 3 and 28 cal-
endar days after symptom onset, with only a few
patients enrolled in the very early period (26). In
contrast, we randomized patients as soon as 12 and
no later than 48 h after symptom onset. Second,
OAT enrolled patients in stable condition without
signs of ongoing ischemia on presentation, whereas
in the present trial, more than 50% of patients had
persistent ischemic symptoms. Third, OAT enrolled
only patients with complete occlusion of the infarct-
related artery, whereas this was not a prerequisite in
our trial.
STUDY LIMITATIONS. Although a total of 132 patients
were to be analyzed according to the a priori sample
size calculation, only 111 patients ultimately entered
the primary endpoint analysis. The study thus did notreach the planned statistical power of 90%. Second,
the signiﬁcantly lower percentage of pre-dilation in
patients assigned to thrombus aspiration might have
introduced a certain degree of bias. Upfront thrombus
aspiration may have more frequently led to decreased
local thrombus burden and adequate visualization
of the culprit site to perform direct stenting. Although
evidence is limited, direct stenting in suitable lesions
may result in a reduction of microvascular injury
(27). The trial did not study the effect of thrombec-
tomy as bailout therapy. Large residual thrombus and
slow or absent ﬂow after unsuccessful conventional
PCI should thus be considered a differing clinical
scenario. Interventionalists were not blinded to
treatment allocation. However, the potential for sig-
niﬁcant bias is limited because all endpoint analyses
were performed by fully blinded investigators.CONCLUSIONS
In patients with subacute STEMI presenting between
12 and 48 h after symptom onset, routine manual
thrombus aspiration before PCI failed to show a sig-
niﬁcant reduction in the primary endpoint of MVO
assessed by CMR compared with conventional PCI
alone. These ﬁndings are supported by a lack of
beneﬁt in angiographic, enzymatic, and clinical sec-
ondary endpoints.
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